PD-L1 IgV affinity peptide with antineoplastic activity, and preparation method and application of thereof
A technology with anti-tumor activity and affinity, applied in anti-tumor drugs, medical preparations containing active ingredients, peptides, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0020] The targeting PD-L1 IgV affinity peptide with anti-tumor activity provided by the present invention, which specifically binds to the PD-L1 IgV region, is screened by phage display peptide library technology, and its amino acid sequence is: Ala-Asn-Gly -Ser-Arg-Leu-Val, namely A-N-G-S-R-L-V, the molecular weight is 715.4.
[0021] Due to the high cost of monoclonal antibody drugs and the inability to produce them on a large scale, we selected the PD-L1 IgV region protein expressed and purified from prokaryotic cells as the target, and screened the protein that can specifically bind to PD-L1 IgV through phage display technology. Peptides to block PD-1 / PD-L1 signaling pathway. For the convenience of those skilled in the art to implement the present invention, its screening process is briefly described as follows:
[0022] The preparation instructions for the media and master solutions used in the screening process are as follows:
[0023] LB liquid medium: Weigh 10 g o...
Embodiment 2
[0075] The affinity peptide of PD-L1 IgV with anti-tumor activity is synthesized by Fomc solid-phase peptide synthesis method, and the synthesis steps are briefly described as follows:
[0076] The main reagents used in the synthesis process are:
[0077] Heading liquid: acetic anhydride / pyridine solution (1:1, v / v);
[0078] Indene detection reagent: A. Ninhydrin / ethanol solution (5%, w / v)
[0079] B. Phenol / Ethanol (4:1, w / v)
[0080] C. Potassium cyanide / pyridine (2%, v / v)
[0081] Deprotection solution: piperidine / DMF solution (20%, v / v);
[0082] Cleavage reagent: by volume, TFA (82.5%), H 2 O (5%), phenol (5%), thioanisole (5%), ethanedithiol (2.5%).
[0083] The synthetic steps are briefly described as follows:
[0084] (1) Swell the resin, add the first amino acid
[0085] A. Swelling resin: Take 0.3~0.5 g Rink resin (the C-terminal amino acid of the peptide connected to the resin is an amide) and place it in a cleaned and dried peptide synthesizer, add an ap...
Embodiment 3
[0127] Taking the PD-L1 IgV affinity peptide with anti-tumor activity prepared in Example 2 as an example, the inventors conducted further in vivo experiments on tumor-bearing mice, and the specific experimental process was as follows:
[0128] Select 24 experimental Balb / c mice, adjust the cell concentration to 5×10 mouse colon cancer (CT26) cells with normal saline (NS) 6 cells / mL, 0.1 mL cell suspension (containing 5×10 5 cells) were inoculated subcutaneously in the armpit of the right forelimb of each Balb / c mouse, and the growth of the subcutaneous tumor was continuously observed.
[0129] The affinity peptide prepared in Example 2 was dissolved in physiological saline to prepare a polypeptide drug, which was subpackaged and stored at -20°C for future use.
[0130] Nine days after inoculation with mouse-derived colon cancer (CT26) cells, the mice were divided into groups according to tumor volume, 6 mice in each group, and divided into negative control group (NS), positi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com